['systemic lupus erythematosus']
['hril-2 active', 'hril-2 placebo']

        Inclusion Criteria:

          -  Meet the American College of Rheumatology criteria for the diagnosis of SLE，1997.

          -  Under standard treatment (≥ 2 months) at the time of inclusion

          -  Background treatment failed to control flares or to permit prednisone tapering

          -  With at least one of the following manifestations: thrombocytopenia,
             disease-associated rash, mouth ulcer, non-infectious type of fever, active vasculitis,
             renal disorder(proteinuria>0.5g/day), neuropsychiatric SLE.

          -  Positive for at least one of the following laboratory tests: ANA>1:160, anti-dsDNA,
             immunoglobulin>20g/L, decreased C3 or C4, leukopenia<3×10^9/L,
             thrombocytopenia<100×10^9/L;

          -  SLE disease activity index(SLEDAI) ≥ 8.

          -  Negative HIV test.

          -  Negative for hepatitis B and C virus.

          -  Negative urine pregnancy test.

          -  Written informed consent form.

        Exclusion Criteria:

          -  Sever chronic liver, kidney, lung or heart dysfunction; (heart failure (≥ grade III
             NYHA), hepatic insufficiency (transaminases> 3N) )

          -  Serious infection such as bacteremia, sepsis;

          -  Cancer or history of cancer cured for less than five years (except in situ carcinoma
             of the cervix or Basocellular carcinoma);

          -  High-dose steroid pulse therapy (>1.5mg/kg) or IV bolus of corticosteroids in the last
             2 months.

          -  History of administration of rituximab or other biologics;

          -  Purified protein derivative (tuberculin) >10mm

          -  Mental disorder or any other chronic illness or drug-abuse that could interfere with
             the ability to comply with the protocol or to give information;

          -  Inability to comply with IL-2 treatment regimen.
      